Tech Company Financing Transactions
Antiverse Funding Round
On 3/3/2026, Antiverse landed $9.3 million in Series A funding from Soulmates Ventures, DOMiNO Ventures and i&i Biotech Fund.
Transaction Overview
Company Name
Announced On
3/3/2026
Transaction Type
Venture Equity
Amount
$9,300,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support expansion of its proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies, while continuing to expand pharmaceutical and research collaborations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
MediCentre, Heath Park 34 Roath Court Road
Cardiff, Wales, CF14 4UJ
UK
Cardiff, Wales, CF14 4UJ
UK
Phone
Undisclosed
Website
Email Address
Overview
It is difficult to discover antibodies against GPCRs because of cells with low receptor count and antibody libraries with poor specificity. At Antiverse, we built a discovery platform that develops cells with high receptor counts (1M per cell) and antibody libraries with high specificity against each target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Murat Tunaboylu
Chief Technical Officer
Benjamin Holland
Browse more venture capital transactions:
Prev: 3/3/2026: RenoFi venture capital transaction
Next: 3/3/2026: Ayar Labs venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs